Clinical Trials Directory

Trials / Conditions / Recurrent Soft Tissue Sarcoma

Recurrent Soft Tissue Sarcoma

16 registered clinical trials studyying Recurrent Soft Tissue Sarcoma — 1 currently recruiting.

StatusTrialSponsorPhase
CompletedAn Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing
NCT05560009
Mayo Clinic—
RecruitingStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04901702
St. Jude Children's Research HospitalPhase 1 / Phase 2
Active Not RecruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
NCT04320888
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
NCT04284774
National Cancer Institute (NCI)Phase 2
Active Not RecruitingIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat
NCT04195555
National Cancer Institute (NCI)Phase 2
CompletedFirst-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tiss
NCT04619056
CEBIOTEXPhase 1
CompletedRadiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas
NCT04398095
Maria Sklodowska-Curie National Research Institute of OncologyN/A
Active Not RecruitingUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi
NCT03698994
National Cancer Institute (NCI)Phase 2
CompletedPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly
NCT03526250
National Cancer Institute (NCI)Phase 2
Active Not RecruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi
NCT03213652
National Cancer Institute (NCI)Phase 2
CompletedPembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
NCT03338959
Fred Hutchinson Cancer CenterPhase 1 / Phase 2
CompletedSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03213678
National Cancer Institute (NCI)Phase 2
CompletedTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213665
National Cancer Institute (NCI)Phase 2
Active Not RecruitingLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213704
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc
NCT03155620
National Cancer Institute (NCI)Phase 2
Active Not RecruitingCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi
NCT02867592
National Cancer Institute (NCI)Phase 2